biOasis Announces Transcend Vector Results on Delivery of Herceptin® to the Brain
biOasis Technologies Inc. (TSX VENTURE:BTI) announced today positive results from its BT2111 program showing that the company's Transcend vector delivers trastuzumab (trade name Herceptin®), across the blood-brain barrier and into the brain tissu ...